The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) invite scientists from academia and the biotechnology industry worldwide to apply for research grants to develop Frontotemporal Dementia (FTD)-specific biomarkers that reflect pathological and clinical differences so that appropriate patients can be selected for clinical trials and responses to investigational treatments can be monitored.
The ADDF and AFTD are particularly interested in defining and validating clinical outcomes for FTD subpopulations for use in clinical trials; FTD-relevant imaging agents; CSF- and plasma-based assays; and TDP-43 and tau-focused biomarkers specifically relevant to FTD populations
The ADDF/AFTD Biomarker Program will provide funding for up to $150,000 each with the possibility of follow-on funding. Applications may be submitted by non-profit academic institutions and for-profit biotechnology companies, both public and private, worldwide. Please note that funding to biotechnology companies is typically made as a program-related investment.
New protein target offers promise for alleviating cognitive decline in Parkinson's disease